Transforming growth factor-beta: A clinical target for the treatment of diabetic nephropathy

Tracy A. McGowan, Yanqing Zhu, Kumar Sharma

Research output: Contribution to journalReview articlepeer-review

39 Scopus citations


Diabetic nephropathy is continuing to rise in incidence, despite awareness of tight glycemic control and blood pressure. The identification that matrix accumulation is driven by transforming grcmdh factor-β (TGF-β) has led to a concerted effort to apply antifibrotic strategies for this disorder. Recent studies have not only demonstrated the beneficial effects of blocking TGF-β on matrix accumulation but have also found that blocking TGF-β may have important hemodynamic effects that are relevant to diabetic complications. In this article, we review the latest knowledge regarding the role of TGF-β in diabetic kidney disease and discuss available and novel therapeutic approaches. The role of a novel antifibrotic drug, pirfenidone, may have important clinical relevance to diabetic nephropathy.

Original languageEnglish (US)
Pages (from-to)447-454
Number of pages8
JournalCurrent Diabetes Reports
Issue number6
StatePublished - Dec 2004
Externally publishedYes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Transforming growth factor-beta: A clinical target for the treatment of diabetic nephropathy'. Together they form a unique fingerprint.

Cite this